The International League Against Epilepsy has revised its epilepsy classification system in an effort to inform epilepsy research and aid drug development.
A "ceiling" may exist for lamotrigine therapy above which remission from seizures may be unlikely.
The system includes a detect-and-respond mode, which is designed to prevent seizures before they start and deliver therapy to stop them if they do.
The CDC has updated the US national estimate of epilepsy prevalence and estimates 3.4 million people are affected by epilepsy.
Patients with sepsis included in this analysis may have presented with other CNS pathologies that could have contributed to seizure risk.
Pregnant women on antiepileptic drugs are at a higher risk of giving birth to a premature and SGA infant.
The FDA has approved an expanded indication for Aptiom to treat pediatric partial-onset seizures.
Briviact was initially approved as adjunct treatment for partial-onset seizures.
Rectal diazepam is currently the only FDA-approved treatment for pediatric status epilepticus.
Over 1% of the US population reported active or current epilepsy in 2015.
While several studies have demonstrated efficacy in refractory epilepsy, it is still not clear how cannabidiol may have an impact on current epilepsy treatments.
Neurology Advisor Articles
- Migraine and Gastrointestinal Disorders: Elucidating an Association
- Brain Health in Contact Sports: Putting It All on the Line
- Alzheimer's Disease Risk Similar in Women and Men With APOE ε3/ε4 Genotype
- Non-Invasive Magnetic Device Approved by FDA for Migraine Tx
- FDA Approves Device for Tx of Chronic Pain